English
Spanish
French
Italian
German
NEWS
Latest News
Why Povorcitinib's JAK1 Mechanism Matters for HS Treatment
Today
In a new HCPLive interview, Dr. Martina Porter explains why HS has lagged behind conditions like psoriasis in effective treatment options, and what povorcitinib's arrival could change. As a selective JAK1 inhibitor, it avoids the JAK2/JAK3 pathways linked to hematopoietic side effects, and its oral, needle-free format may appeal to patients hesitant about injections. Because JAK1 inhibition works through a broader pathway than TNF-alpha or IL-17 inhibition, Porter suggests it could offer an alternative for patients who haven't responded to existing biologics, particularly those with early nodular or severe tunneling disease.
Read more
Topical Ruxolitinib Shows Promise for Early-Stage Hidradenitis Suppurativa
July 27, 2026
New Phase 2 data suggest that topical ruxolitinib cream may help address a major unmet need in mild-to-moderate hidradenitis suppurativa. Patients treated with the JAK1/2 inhibitor experienced significant reductions in inflammatory lesions, high clinical response rates, and a favorable safety profile, highlighting its potential as a targeted therapy for early-stage disease.
Read more
The First Doctor an HS Patient Sees Is Usually Not a Dermatologist
July 22, 2026
Most people with hidradenitis suppurativa don't meet a dermatologist first. They meet primary care, OB/GYN, urgent care, or the ER, and that's usually where the 7 to 10 year delay to diagnosis begins. Dr. Steven Daveluy, who has spent over a decade teaching non-dermatology clinicians about HS, breaks down the single question that can catch the disease early, what frontline providers can do while patients wait to see a specialist, and why the upcoming AAD/HSF guidelines could change the financial and clinical case for treatments like laser hair removal.
Read more
Avalo Advances Long-Acting IL-1β Antibody Program for Hidradenitis Suppurativa
July 20, 2026
Avalo Therapeutics has announced the development of AVTX-010, a next-generation anti-IL-1β antibody designed to provide longer dosing intervals for patients with hidradenitis suppurativa. Building on promising Phase 2 results for abdakibart, the program aims to improve treatment convenience, adherence, and patient experience while expanding future therapeutic options in HS.
Read more
Criteria for Hidradenitis Suppurativa Competence Centers
July 12, 2026
An international Delphi consensus involving clinicians and patient representatives from 16 countries has established 23 core criteria for Hidradenitis Suppurativa Competence Centers. The recommendations provide a framework for delivering consistent, multidisciplinary, patient-centered HS care and may help improve access to specialized treatment worldwide.
Read more
Ambulatory Surgery May Be an Option for Troublesome Hidradenitis Suppurativa
July 10, 2026
Surgery isn't just a last resort anymore. A leading dermatologist explains why ambulatory surgery can offer faster relief for troublesome HS lesions, even for patients currently trying today's targeted biologic therapies. Learn when surgical intervention might be worth considering sooner rather than later.
Read more
Beyond the Surface: July 2026
July 8, 2026
Catch the latest from the Hidradenitis Suppurativa Foundation—SHSA 2026 in Tucson, new HS clinical guideline insights, updated resources, and upcoming deadlines you won't want to miss.
Read more
HS in Skin of Color: Bridging Gaps in Diagnosis, Treatment, and Equity
June 22, 2026
In this episode of Skin of Color Savvy, Tiffany Mayo, MD, Steven Daveluy, MD, and patient advocate Jasmine Ivanna Espy unpack the unique challenges of hidradenitis suppurativa (HS) in patients with skin of color, from delayed diagnosis to treatment hesitancy and access barriers. Blending clinical expertise with lived experience, the discussion highlights practical strategies to improve recognition, expand therapeutic confidence, and center patient voices in more equitable HS care.
Read more
The Emerging Role of Povorcitinib in Moderate to Severe Hidradenitis Suppurativa
June 16, 2026
A potential new chapter in hidradenitis suppurativa (HS) treatment is unfolding with povorcitinib, an oral JAK1-selective inhibitor showing promising phase 3 results. In patients with moderate to severe disease—many with prior biologic exposure—clinical response rates improved over time, alongside meaningful reductions in pain and draining tunnels. With generally favorable tolerability and the convenience of once-daily dosing, povorcitinib could help address persistent gaps in HS care and expand options beyond injectable biologics.
Read more
Expanding the HS Treatment Landscape: From Single-Pathway Therapy to Personalized Care
June 15, 2026
The hidradenitis suppurativa (HS) treatment landscape is evolving rapidly, with dozens of biologics and small-molecule therapies in development targeting multiple inflammatory pathways. In this interview, Leandra A. Barnes, MD, FAAD, discusses the shift toward more personalized, patient-centered care, the challenges of treatment dissatisfaction and access barriers, and the promise of emerging therapies that may help improve outcomes for people living with HS.
Read more